Aaipharma Inc

Drug maker AaiPharma Inc. said that it had received subpoenas from a federal grand jury for testimony and a variety of documents and that it had been notified that it might soon receive a subpoena from the Securities and Exchange Commission. The company has said it is investigating "sales abnormalities" involving its asthma drug and painkillers. Its chief executive has resigned, and it has received a Nasdaq delisting notice. AaiPharma said it would cooperate with the investigations.

Drug maker AaiPharma Inc. said that it had received subpoenas from a federal grand jury for testimony and a variety of documents and that it had been notified that it might soon receive a subpoena from the Securities and Exchange Commission. The company has said it is investigating "sales abnormalities" involving its asthma drug and painkillers. Its chief executive has resigned, and it has received a Nasdaq delisting notice. AaiPharma said it would cooperate with the investigations.

Andrx Corp. said it expects U.S. regulatory approval of its generic version of heartburn and ulcer medicine Prilosec to be delayed because of issues raised by Britain's AstraZeneca, the original maker of the blockbuster drug, and AaiPharma Inc., which holds related patents.